---
title: "Fate Therapeutics updates corporate presentation; highlights FT819 Phase 1/2 progress, FT836 enrollment, $174.8M cash"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/288772187.md"
description: "Fate Therapeutics updated its corporate presentation, highlighting FT819 Phase 1 safety and efficacy, with RECLAIM-LN Phase 2 enrollment planned for late 2026. FT836 is enrolling in a pan-solid tumor Phase 1 trial showing preliminary activity. Financially, the company reported $174.8M in cash and investments as of Q1 2026, with a runway into 2028 and a 20% year-over-year reduction in operating expenses."
datetime: "2026-06-04T20:43:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/288772187.md)
  - [en](https://longbridge.com/en/news/288772187.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/288772187.md)
generator: "portal-rs"
---

# Fate Therapeutics updates corporate presentation; highlights FT819 Phase 1/2 progress, FT836 enrollment, $174.8M cash

**Fate Therapeutics updated its corporate presentation highlighting FT819 clinical progress, FT836 enrollment and a Q1 2026 cash balance of $174.8M.**

**Key Highlights:**

-   Updated corporate presentation released for EULAR 2026, attached as Exhibit 99.1 to the 8-K.
-   FT819 Phase 1 shows favorable safety (no DLTs, no grade ≥3 CRS/ICANS/GvHD) and rapid, sustained clinical improvements.
-   RECLAIM-LN Phase 2 (900M single dose, bendamustine conditioning) planned to start 2H 2026; enrollment N=53, BLA targeted in 2028.
-   FT836 pan–solid tumor Phase 1 now enrolling with preliminary anti-tumor activity and tumor trafficking without conditioning chemo.
-   Q1 2026 financial snapshot: $174.8M cash and investments, runway into 2028, and a 20% YoY OpEx reduction with $8.6M total quarterly savings vs Q1 2025.

Original SEC Filing: FATE THERAPEUTICS INC \[ FATE \] - 8-K - Jun. 04, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [FATE.US](https://longbridge.com/en/quote/FATE.US.md)

## Related News & Research

- [Fate Therapeutics joins Cantor Global Healthcare Conference fireside chat on FT819 autoimmune CAR-T program](https://longbridge.com/en/news/297902766.md)
- [Fate Therapeutics Expands Into Autoimmune Disease With New FT839 Trial](https://longbridge.com/en/news/297812155.md)
- [Transgene says TG4050 posts 100% 3-year disease-free survival in Phase 1 head-and-neck cancer trial](https://longbridge.com/en/news/297809436.md)
- [09:41 ETMammotome Accelerates Production as Public Health Response to Nationwide Breast Biopsy Needle Shortage](https://longbridge.com/en/news/297924402.md)
- [Orum to begin Phase I trial of ORM-1153 after FDA clearance](https://longbridge.com/en/news/298030380.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**